BACKGROUND: Since the FDA Black box warning in 2004, there has been a 58% drop in antidepressant use among children and adolescents with depression. Paralleling this decrease is an associated increase in completed suicides in youth. To date, no study has examined, on a clinician level, the changes in practice that have occurred subsequent to the FDA warning. OBJECTIVE: To examine changes in pediatrician clinical practice resulting from the FDA warning on antidepressants. METHODS: Subjects were recruited through a national program sponsored by the Canadian Pediatric Society that regularly surveys practicing pediatricians. The mail survey inquired about knowledge of the Black-box warning, whether their practice changed and reasons for changes in prescribing practices with antidepressants after the warning. We surveyed a total of 2395 pediatricians in Canada. RESULTS: Of the 1748 eligible pediatricians, 670 (38%) responded.Seventy-two percent (n = 484) of respondents were aware of the FDA warning. Of the 484 respondents who were aware of the warning, 80% (n = 386) changed their prescribing practices including 32% (n = 154) who followed their patients more closely. Seven percent (n = 35) stopped treatment with SSRIs in at least one patient. Physicians who had observed worsening depression/suicidality were more likely to discontinue treatment with SSRI's compared to those who had not observed these side effects previously (25% versus 6%, p < 0.001). CONCLUSION: This is the first national study to examine individual pediatrician practice changes in antidepressant use subsequent to the FDA warning. Further research is needed to better understand the reasons for these changes to aid in the development of strategies that could help clinicians to optimally integrate these warnings into clinical practice.
BACKGROUND: Since the FDA Black box warning in 2004, there has been a 58% drop in antidepressant use among children and adolescents with depression. Paralleling this decrease is an associated increase in completed suicides in youth. To date, no study has examined, on a clinician level, the changes in practice that have occurred subsequent to the FDA warning. OBJECTIVE: To examine changes in pediatrician clinical practice resulting from the FDA warning on antidepressants. METHODS: Subjects were recruited through a national program sponsored by the Canadian Pediatric Society that regularly surveys practicing pediatricians. The mail survey inquired about knowledge of the Black-box warning, whether their practice changed and reasons for changes in prescribing practices with antidepressants after the warning. We surveyed a total of 2395 pediatricians in Canada. RESULTS: Of the 1748 eligible pediatricians, 670 (38%) responded.Seventy-two percent (n = 484) of respondents were aware of the FDA warning. Of the 484 respondents who were aware of the warning, 80% (n = 386) changed their prescribing practices including 32% (n = 154) who followed their patients more closely. Seven percent (n = 35) stopped treatment with SSRIs in at least one patient. Physicians who had observed worsening depression/suicidality were more likely to discontinue treatment with SSRI's compared to those who had not observed these side effects previously (25% versus 6%, p < 0.001). CONCLUSION: This is the first national study to examine individual pediatrician practice changes in antidepressant use subsequent to the FDA warning. Further research is needed to better understand the reasons for these changes to aid in the development of strategies that could help clinicians to optimally integrate these warnings into clinical practice.
Authors: Cynthia Haddad; Alexis Sidoroff; Sylvia H Kardaun; Maja Mockenhaupt; Daniel Creamer; Ariane Dunant; Jean-Claude Roujeau Journal: Drug Saf Date: 2013-08 Impact factor: 5.606
Authors: Orestis A Panagiotou; Despina G Contopoulos-Ioannidis; Panagiotis N Papanikolaou; Evangelia E Ntzani; John P A Ioannidis Journal: J Gen Intern Med Date: 2011-02-01 Impact factor: 5.128
Authors: Sigrid Piening; Flora M Haaijer-Ruskamp; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol Journal: Drug Saf Date: 2012-11-01 Impact factor: 5.606
Authors: Sarah A Ting; Ashley F Sullivan; Edwin D Boudreaux; Ivan Miller; Carlos A Camargo Journal: Gen Hosp Psychiatry Date: 2012-05-02 Impact factor: 3.238
Authors: Kevin M Gray; Matthew J Carpenter; Nathaniel L Baker; Karen J Hartwell; A Lee Lewis; D Walter Hiott; Deborah Deas; Himanshu P Upadhyaya Journal: J Subst Abuse Treat Date: 2010-10-08
Authors: Greta A Bushnell; Til Stürmer; Sonja A Swanson; Alice White; Deborah Azrael; Virginia Pate; Matthew Miller Journal: Psychiatr Serv Date: 2015-11-16 Impact factor: 3.084